Frank e. Thomas

Frank e. Thomas (chief executive) discloses dealings in 3 companies, chiefly Orchard Therapeutics plc, Spero Therapeutics, Inc. and Larimar Therapeutics, Inc. We count 10 filings; the first trade dates from 1 April 2022 and the latest from 27 February 2026.

The open-market record is one-sided, with 3 purchases worth €48k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 4 share grants and 2 option exercises. 2026 to date brings 1 purchase and no sales.

In size, the median ticket on the buying side is €21k. On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 2 March 2026 with an open-market purchase (€21k) in Larimar Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.